It is known that wild type TP53 can contribute to drug resistance in colon cancer cell lines [45] and cells with wild type TP53 were relatively resistant to trametinib in a profiling study in a 44-cell line panel [31]. Here, TP53 is linked to malignant colon neoplasm.